comparemela.com

Latest Breaking News On - Mannkind corp - Page 2 : comparemela.com

Jim Cramer Says You Should Avoid These 11 Stocks

In this article, we will take a detailed look at Jim Cramer Says You Should Avoid These 11 Stocks. For a quick overview of such stocks, read our article Jim Cramer Says You Should Avoid These 5 Stocks.

Human Insulin Drugs Market In Brazil 2023-2028: Market Analysis, Drivers, Restraints, Opportunities, and Threats

2023 Inhalers Pipeline Research Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies

Shares Up Mostly - San Fernando Valley Business Journal

Although the stock markets overall enjoyed a banner year in 2023 – the S&P 500 was up 24% – Valley-area stocks, with a few notable exceptions, had a far more modest year.

MannKind Corp : Sagard Healthcare Purchases 1% Royalty In Tyvaso DPI Net Sales

MannKind Corp. (MNKD) has sold a 1% royalty in net sales of Tyvaso DPI inhalation powder to Sagard Healthcare in exchange for up to $200 million, including the purchase price of $150 million and an additional potential milestone payment of up to $50 million.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.